⌕
AbCellera Biologics · ABCL · Nasdaq
Tenet 49 · Mixed
Compare
$11.03−0.81%At closeTenet 49 · Mixed
$11.03−0.09 (−0.81%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

AbCellera Biologics (ABCL) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Seeking AlphaNov 17, 2026 · 13:02 ET
AbCellera Biologics Inc. (ABCL) Presents at UBS Global Biopharma Conference 2026 Transcript

AbCellera Biologics Inc. (ABCL) Presents at UBS Global Biopharma Conference 2026 Transcript…

● MarketBeatNov 16, 2026 · 17:12 ET
AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment

AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot flash treatment ABCL635 into late-stage studies, with a registrational trial potentially starting around the middle of 2027, Chief Executive C…

● Seeking AlphaNov 13, 2026 · 18:59 ET
AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

AbCellera Biologics Inc. ( ABCL ) Stifel 2026 Healthcare Conference 2026 November 10, 2026 7:00 PM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Conference Call Participants Stephen Willey - Stif…

● Zacks Investment ResearchNov 12, 2026 · 10:41 ET
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?

Here is how AbCellera Biologics Inc. (ABCL) and Editas Medicine (EDIT) have performed compared to their sector so far this year.…

● MarketBeatNov 12, 2026 · 08:14 ET
AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results

AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot-flash treatment ABCL635 into late-stage development next year after a midstage study produced stronger-than-expected efficacy results, CEO Car…

● Seeking AlphaNov 9, 2026 · 23:10 ET
AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript…

● MarketBeatNov 9, 2026 · 21:16 ET
What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call

AbCellera Biologics NASDAQ: ABCL plans to advance its experimental hot flash treatment ABCL635 into late-stage development in 2027 after reporting positive mid-stage results, while shelving further development of a separ…

● Zacks Investment ResearchNov 9, 2026 · 18:36 ET
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.19 per share a year ago.…

● Business WireNov 9, 2026 · 16:05 ETCOMPANY'S OWN WORDS
AbCellera Reports Q3 2026 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2026 Business Results.…

● Business WireOct 8, 2026 · 16:05 ETCOMPANY'S OWN WORDS
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting.…

● Business WireOct 1, 2026 · 16:05 ETCOMPANY'S OWN WORDS
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026.…

● Defense WorldOct 1, 2026 · 04:15 ET
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of “Moderate Buy” from Analysts

AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. One investment an…

● Zacks Investment ResearchSep 22, 2026 · 11:21 ET
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.…

● Business WireSep 16, 2026 · 16:05 ETCOMPANY'S OWN WORDS
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.…

● Business WireSep 2, 2026 · 16:05 ETCOMPANY'S OWN WORDS
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.…

● Defense WorldSep 2, 2026 · 04:36 ET
BlackRock Inc. Makes New Investment in AbCellera Biologics Inc. $ABCL

BlackRock Inc. purchased a new position in shares of AbCellera Biologics Inc. (NASDAQ: ABCL) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (…

● BenzingaAug 25, 2026 · 14:38 ET
What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.…

Business Wire · Nov 9, 2026

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA35−0.4%
ABR4−2.6%
INTC4−0.5%
LAW4−8.6%

Article counts from the last market-wide feed page, across every symbol we track and not just ABCL · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.